UDP-xylose is an important sugar nucleoside diphosphate that plays a key role in cells. The synthesis of UDP-xylose is usually accomplished through a multi-step biosynthetic pathway, which involves the catalytic reactions of multiple enzymes, including UDP-glucose dehydrogenase and xylosyltransferase. These enzymes start with the substrate glucose and a series of coenzymes such as NAD+, and ultimately generate UDP-xylose through a series of catalytic reactions. UDP-xylose serves as an important substrate involved in a variety of biological processes, such as glycosylation modification and cell wall synthesis. Therefore, inhibitors targeting UDP-xylose may become potential drug targets for the treatment of certain diseases. CD BioGlyco provides professional UDP-xylose inhibitor development services.
CD BioGlyco uses a high-throughput screening approach to identify candidate compounds with potential UDP-xylose inhibitory activity from compound libraries, followed by structural optimization of the candidate compounds to improve their activity and selectivity.
CD BioGlyco uses computer-aided drug design, molecular simulation, and other technologies to design and optimize UDP-xylose inhibitors for target enzymes.
Based on the designed enzyme inhibitor scheme, CD BioGlyco synthesizes and optimizes candidate compounds to improve their drug properties, pharmacokinetic properties, and toxicological characteristics, and conducts isolation, purification, and structural identification of the synthesized compounds.
We evaluate the UDP-xylose inhibitory activity and cytotoxicity of candidate compounds in vitro cell experiments. By measuring the inhibitory constants and kinetic parameters of candidate compounds on the target enzyme, we further studied its interaction mechanism with UDP-xylose synthase.
Fig.1 UDP-Xylose inhibitor development service. (CD BioGlyco)
Technology: KM Plotter, Knockout of Ugdh
Journal: Cancer Letters
Results: The authors investigated the importance of multiple UDP-glucose pathways (including UDP-xylose) in breast cancer metastasis. The authors knocked out Ugdh, a rate-limiting gene that mediates UDP-glucuronide production, in mouse breast cancer cells and found that Ugdh knockout impaired tumor growth and metastasis in vivo. Moreover, the authors used online tools to evaluate the relationship between high expression of genes in the UDP-glucose pathway and patient survival. Results indicated that Ugdh expression increases UDP-glucuronide production, whereas low UXS1 decreases UDP-glucuronide.
Fig.2 High Ugdh and low UXS1 expression versus patient survival. (Teoh, et al., 2020)
CD BioGlyco has efficient project management capabilities and a one-stop Inhibitor Development Services, and we will provide clients with excellent UDP-xylose inhibitor development services. Please feel free to contact us if you would like to learn more about specific service details.